NCT06638021 Targeted EHR-based Communication of Diagnostic Uncertainty in the ED
| NCT ID | NCT06638021 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Thomas Jefferson University |
| Condition | Diagnostic Uncertainty |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-11-05 |
| Primary Completion | 2026-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2024-11-05 with a primary completion date of 2026-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of the clinical trial is to evaluate the preliminary effectiveness and the implementation feasibility of the Targeted EHR-based Communication about Uncertainty (TECU) strategy in improving the quality of care transitions from the emergency department (ED) to home. The overall specific aims related to the trial are to test the preliminary effectiveness of TECU compared to standard of care in reducing patient uncertainty and return ED visits and evaluate the adoption of TECU, exploring patient and clinician barriers and facilitators to TECU implementation.
Eligibility Criteria
Patient Inclusion Criteria: * age 18 years or older * English language speaking * assigned a symptom-based diagnosis in the EHR clinical impression * planned for discharge from the ED during the enrollment visit * able to complete follow up assessments in 2 and 30 days * TECU best practice advisory (BPA) electronic health record alert activates during their discharge process Patient Exclusion Criteria: * under the age of 18 years * non-English speaking * clinically unstable, psychologically impaired or intoxicated, or otherwise unable to provide informed consent as judged by research staff member * admitted to hospital * unable to complete follow up in 2 and 30 days * previously enrolled in this study (during a prior ED visit)
Contact & Investigator
Kristin L Rising, MD, MS
PRINCIPAL INVESTIGATOR
Thomas Jefferson University
Frequently Asked Questions
Who can join the NCT06638021 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Diagnostic Uncertainty. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06638021 currently recruiting?
Yes, NCT06638021 is actively recruiting participants. Contact the research team at kristin.rising@jefferson.edu for enrollment information.
Where is the NCT06638021 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT06638021 clinical trial?
NCT06638021 is sponsored by Thomas Jefferson University. The principal investigator is Kristin L Rising, MD, MS at Thomas Jefferson University. The trial plans to enroll 300 participants.